Get cozy with these new drugs for diabetes. Don’t be scared, they won’t bite. On this episode,  we interview Endocrinologist and current president of AACE, Dr. Jonathan D. Leffert, MD, FACP, FACE, ECNU about how to utilize the myriad of new diabetes drugs on the marketplace including SGLT2 inhibitors, DPP4 inhibitors, GLP1 agonists, and new ultra long acting insulins. Plus, we’ll teach you how to choose between agents, common side effects, A1C goals, and the cardiovascular benefits of these newer agents. Full show notes available at http://thecurbsiders.com/podcast Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Case: Case from Kashlak Memorial Hospital: 49 yo M with HTN, BMI 29, hyperlipidemia, family history of premature CAD (dad age 45yo), and DM2 with A1C increase from 6.4% to 9% while on metformin monotherapy. Time Stamps 00:00 Intro 04:33 Getting to know our guest 09:50 Clinical case of diabetes 12:40 Latent autoimmune diabetes 15:16 Life expectancy and A1C goal 16:47 Anemia’s effect on A1C 18:40 Back to our case, choice of agent 20:57 Lifestyle changes effect on A1C 22:55 Starting an SGLT2 inhibitor, what to look for 26:45 SGLT2 inhibitor use in patient already on diuretic 27:53 Discussion of CV risk reduction and newer DM meds 33:27 Euglycemic DKA 34:30 Choice of agent GLP1 vs SGLT2 37:10 Use of DPP4 inhibitors 38:55 Back to the case 39:37 Degludec, long acting insulin 41:34 Clinical case conclusion 43:03 Take home points 45:15 Outro Tags: diabetes, medications, glucose, insulin, oral, therapy, drug, hypoglycemia, a1c, blood, cardiac, risk, assistant, care, education, doctor, family, foam, foamed, health, hospitalist, hospital, internal, internist, nurse, medicine, medical, primary, physician, resident, student